Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of GBP 97.76 billion. The enterprise value is 109.99 billion.

Market Cap	97.76B
Enterprise Value	109.99B

Important Dates

The last earnings date was Thursday, April 24, 2025.

Earnings Date	Apr 24, 2025
Ex-Dividend Date	Jun 13, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	+0.28%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 21.17 and the forward PE ratio is 12.61.

PE Ratio	21.17
Forward PE	12.61
PS Ratio	4.40
PB Ratio	6.62
P/TBV Ratio	n/a
P/FCF Ratio	12.83
P/OCF Ratio	12.18
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.46, with an EV/FCF ratio of 14.44.

EV / Earnings	23.82
EV / Sales	5.06
EV / EBITDA	10.46
EV / EBIT	13.27
EV / FCF	14.44

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 1.31.

Current Ratio	1.37
Quick Ratio	1.06
Debt / Equity	1.31
Debt / EBITDA	1.80
Debt / FCF	2.53
Interest Coverage	11.14

Financial Efficiency

Return on equity (ROE) is 32.66% and return on invested capital (ROIC) is 15.79%.

Return on Equity (ROE)	32.66%
Return on Assets (ROA)	12.14%
Return on Invested Capital (ROIC)	15.79%
Return on Capital Employed (ROCE)	24.84%
Revenue Per Employee	1.26M
Profits Per Employee	262,321
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.45

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +56.31% in the last 52 weeks. The beta is 0.34, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.34
52-Week Price Change	+56.31%
50-Day Moving Average	107.94
200-Day Moving Average	93.63
Relative Strength Index (RSI)	50.06
Average Volume (20 Days)	3,373

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.38

Income Statement

In the last 12 months, Gilead Sciences had revenue of GBP 22.24 billion and earned 4.62 billion in profits. Earnings per share was 3.66.

Revenue	22.24B
Gross Profit	17.41B
Operating Income	8.48B
Pretax Income	5.28B
Net Income	4.62B
EBITDA	10.62B
EBIT	8.48B
Earnings Per Share (EPS)	3.66

Full Income Statement

Balance Sheet

The company has 6.74 billion in cash and 19.31 billion in debt, giving a net cash position of -12.57 billion.

Cash & Cash Equivalents	6.74B
Total Debt	19.31B
Net Cash	-12.57B
Net Cash Per Share	n/a
Equity (Book Value)	14.77B
Book Value Per Share	11.91
Working Capital	3.53B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.02 billion and capital expenditures -404.02 million, giving a free cash flow of 7.62 billion.

Operating Cash Flow	8.02B
Capital Expenditures	-404.02M
Free Cash Flow	7.62B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.29%, with operating and profit margins of 38.11% and 20.76%.

Gross Margin	78.29%
Operating Margin	38.11%
Pretax Margin	23.75%
Profit Margin	20.76%
EBITDA Margin	47.76%
EBIT Margin	38.11%
FCF Margin	34.26%

Dividends & Yields

This stock pays an annual dividend of 2.41, which amounts to a dividend yield of 2.49%.

Dividend Per Share	2.41
Dividend Yield	2.49%
Dividend Growth (YoY)	1.19%
Years of Dividend Growth	3
Payout Ratio	66.02%
Buyback Yield	-0.28%
Shareholder Yield	2.22%
Earnings Yield	4.72%
FCF Yield	7.79%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.19.

Altman Z-Score	3.19
Piotroski F-Score	n/a